Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/HEARTVIEWS.HEARTVIEWS_155_20 http://scihub22266oqcxt.onion/10.4103/HEARTVIEWS.HEARTVIEWS_155_20 33688415!7899000!33688415     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Heart+Views 2020 ; 21 (3): 220-224 Nephropedia Template TP {{tp|p=33688415|t=2020. SARS-CoV-2 Infection in the Heart Transplant Recipient |pdf=|usr=}}{{33688415}} gab.com Text SARS-CoV-2 Infection in the Heart Transplant Recipient JO: Heart Views http://www.kidney.de/pget.php?&tw=1&pmid=33688415 #FOAvip Review of the literature and reported case series has not reported an increased risk of SARS-CoV-2 infection in heart transplant recipients. However, this population is at increased risk of a more severe infection with increased mortality because of age and the presence of multiple comorbid conditions There is no significant difference in presenting symptoms in transplant recipients as compared to nontransplant patients, although diarrhea has been reported to be more frequent in transplant patients, a common side effect of immunosuppressive medications. Standard preventive measures have been shown to be equally protective in heart transplant recipients. Risk factors for severe disease and mortality are similar in both transplant recipients and nontransplant patients and include older age and the presence of comorbidities hypertension being the most common. The SARS-CoV-2 infection did not increase the risk of transplant allograft rejection. Currently, there are no specific treatment recommendations for SARS-CoV-2 infection in transplant recipients. However, the International Society of Heart and Lung and Transplant has issued guidance on how to modulate immunosuppressive therapy during SARS-CoV-2 infection. Twit Text FOAVip SARS-CoV-2 Infection in the Heart Transplant Recipient ????Heart Views http://www.kidney.de/pget.php?&tw=1&pmid=33688415 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33688415 #FOAvip English Wikipedia <ref>{{Cite pmid|33688415}}</ref> SARS-CoV-2 Infection in the Heart Transplant Recipient #MMPMID33688415 Shah JZ; Elbdri S; Patel AA; Badr AMH Heart Views 2020[Jul]; 21 (3): 220-224 PMID33688415show ga Review of the literature and reported case series has not reported an increased risk of SARS-CoV-2 infection in heart transplant recipients. However, this population is at increased risk of a more severe infection with increased mortality because of age and the presence of multiple comorbid conditions There is no significant difference in presenting symptoms in transplant recipients as compared to nontransplant patients, although diarrhea has been reported to be more frequent in transplant patients, a common side effect of immunosuppressive medications. Standard preventive measures have been shown to be equally protective in heart transplant recipients. Risk factors for severe disease and mortality are similar in both transplant recipients and nontransplant patients and include older age and the presence of comorbidities hypertension being the most common. The SARS-CoV-2 infection did not increase the risk of transplant allograft rejection. Currently, there are no specific treatment recommendations for SARS-CoV-2 infection in transplant recipients. However, the International Society of Heart and Lung and Transplant has issued guidance on how to modulate immunosuppressive therapy during SARS-CoV-2 infection. äSARS-CoV-2 Infection in the Heart Transplant Recipient (epmc).pdf DeepDyve Pubget Overpricing